CN1185953A - Eye drop containing rich oxygen and preparation thereof - Google Patents
Eye drop containing rich oxygen and preparation thereof Download PDFInfo
- Publication number
- CN1185953A CN1185953A CN96116645A CN96116645A CN1185953A CN 1185953 A CN1185953 A CN 1185953A CN 96116645 A CN96116645 A CN 96116645A CN 96116645 A CN96116645 A CN 96116645A CN 1185953 A CN1185953 A CN 1185953A
- Authority
- CN
- China
- Prior art keywords
- oxygen
- sod
- taurine
- edta
- cellulose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicinal Preparation (AREA)
Abstract
An oxygen-enriched eye drops is an aqueous solution with oxygen content of 25-30 mg/l, which contains such components (mg/ml) as sodium chloride (5-7), boric acid (0-2.5), borax (0-1), Na2HP (0-1.5), NaH2PO (0-1.8), polyoxyethylene-polyoxypropylene block copolymer (3-7), TW-80 (0-4.5), PVP (0-9.5), hydroxymethylpropyl cellulose (0-9), hydroxyethylcellulose (0-3.5), taurine (0-3), borneol (1.5-2), EDTA-Na2 (0-1.2), sorbic acid (0-0.6), SOD (0-2.5) and perfluorane (0-2.8).
Description
The present invention relates to a kind of easypro eye liquid and production technology thereof, be specifically related to a kind of oxygen enrichment easypro eye liquid and production technology thereof.
As everyone knows, popular in the market contact lens care solution, only be a kind of lens care product that when eyeglass is in non-working condition, uses, and can not in time the eyeglass situation in the use be improved or help, so can not moisten and nutrition to eyes.
The object of the present invention is to provide the practical problem of a kind of effective solution cornea anoxia and eyeglass cleaning in wearing the mirror process, to promote the metabolism of cornea tissue, provide eyes nutrition, anti-eye strain and the improvement oxygen enrichment easypro eye liquid and the production technology thereof of eye situation.
Above-mentioned purpose of the present invention realizes in the following manner: a kind of oxygen enrichment eye liquid that relaxes, by comprising that every milliliter of oxygen content is the component that contains following mg weight in the aqueous solution of 25mg/L-30mg/L:
Sodium chloride 5.0-7.0
Boric acid 0-2.5
Borax 0-1.0
Sodium dihydrogen phosphate 0-1.8
Sodium hydrogen phosphate 0-1.5
*POLOXAMER407??????3.0-7.0
TW-80???????????????0-4.5
**PVP??????????????0-9.5
Hydroxymethyl-propyl cellulose 0-9.0
Hydroxyethyl-cellulose 0-3.5
Taurine 0-3.0
Borneolum Syntheticum 1.5-2.0
EDTA-Na2????????????0-1.2
Sorbic acid 0-0.6
SOD 0-2.5 and
C
4-C
16Perfluor alkane 0-2.8.* be polyox-yethylene-polyoxypropylene block copolymer.* is a polyvinyl pyrrolidone.
The production technology of the easypro eye of a kind of oxygen enrichment liquid, comprise and to be selected from a kind of following formula constituent by being dissolved in water, leaving standstill, filtering, it is 99.99% oxygen that filtrate feeds purity, the control oxygen flow is at 1.5 liters/minute, be 〉=25mg/l that the formula ratio of described component (mg/ml) is selected from following prescription until the aqueous solution oxygen content:
Sodium chloride 5.0-7.0
Boric acid 0-2.5
Borax 0-1.0
Sodium dihydrogen phosphate 0-1.8
Sodium hydrogen phosphate 0-1.5
POLOXAMER407????????3.0-7.0
TW-80???????????????0-4.5
PVP?????????????????0-9.5
Hydroxymethyl-propyl cellulose 0-9.0
Hydroxyethyl-cellulose 0-3.5
Taurine 0-3.0
Borneolum Syntheticum 1.5-2.0
EDTA-Na2????????????0-1.2
Sorbic acid 0-0.6
SOD 0-2.5 and
C
4-C
16Perfluor alkane 0-2.8.
Advantage of the present invention is tangible, and oxygen enrichment of the present invention relaxes eye liquid except the tax oxygen function of humidification with general eye liquid and uniqueness, also has following six big characteristics or effects:
1. improve the tear oxygen content, alleviate the deficiency of cornea oxygen supply, promote the metabolism of cornea;
2. cleaning eyes and intraocular lens prevent that the contaminated thing of eyeglass from adhering to and corrode.Reduce the injury of foreign body, help the removing of intraocular foreign body eyes;
3. composition is safe and reliable, does not contain eyes or eyeglass are produced the harmful substance of ill effect, so irritated personage also can relievedly use;
4. eyes nutrition is provided, effectively eliminates the eyestrain, delay the aging of eyes, improve with the eye situation;
5. moisten eyes and eyeglass, eliminate the xerophthalmia symptom, promote the tear circulation, stop the water evaporates of eyeglass, improve the comfort that stealthy eyeball mirror is worn usefulness;
6. have good antibiotic, antiinflammatory, analgesic, analgesic activity, can effectively prevent contact lens to wear, simultaneously various conjunctivitis, point-like exfoliation of corneal epithelium be had good preventing and therapeutical effect with the improper and complication that causes (as the limbus of corneae blood vessel hyperplasia, corneal sensation is blunt and macropapillary conjunctivitis GPC etc.);
The oxygen enrichment eye liquid that relaxes can effectively prolong the wearing time of eyeglass, guarantees safe in utilizationly, is widely used in various contact lens wearers' daily nursing and health care.
Oxygen enrichment relax eye liquid person that also is applicable to the twenty-twenty vision or do not wear the contact lens daily profit eye of person and eye care.
The present invention is described in further detail below with reference to specific embodiment.Embodiment 1-8:
1. fill a prescription: (every milliliter contains a milligram number)
* be polyox-yethylene-polyoxypropylene block copolymer.* is a polyvinyl pyrrolidone.
Composition | Embodiment 1 | Embodiment 2 | Embodiment 3 | Embodiment 4 | Embodiment 5 | Embodiment 6 | Embodiment 7 | Embodiment 8 |
Sodium chloride | ????5.63 | ????7.12 | ????6.35 | ????5.10 | ????6.68 | ????7.43 | ????5.19 | ????6.33 |
Boric acid | ????1.86 | ????1.64 | ????1.35 | ????2.13 | ?????- | ?????- | ?????- | ?????- |
Borax | ????0.69 | ????0.62 | ????0.58 | ????0.83 | ?????- | ?????- | ?????- | ?????- |
Sodium dihydrogen phosphate | ?????- | ?????- | ?????- | ?????- | ????1.35 | ????1.65 | ????1.36 | ????1.35 |
Sodium hydrogen phosphate | ?????- | ?????- | ?????- | ?????- | ????1.24 | ????1.32 | ????1.25 | ????1.24 |
???? *POLOXAMER407 | ????3.51 | ????5.12 | ????6.10 | ????6.25 | ????3.12 | ????3.45 | ????6.50 | ????5.14 |
????TW-80 | ????2.56 | ????1.23 | ?????- | ?????- | ????4.26 | ????1.36 | ?????- | ?????- |
???? **PVP | ?????- | ?????- | ????8.15 | ????6.12 | ?????- | ????6.38 | ?????- | ????9.32 |
Hydroxymethyl-propyl cellulose | ????7.50 | ????5.23 | ?????- | ????2.15 | ????5.36 | ?????- | ????8.64 | ?????- |
Hydroxyethyl-cellulose | ?????- | ?????- | ?????- | ?????- | ????2.69 | ????3.47 | ?????- | ?????- |
Taurine | ????2.00 | ????2.00 | ????2.50 | ?????- | ????2.65 | ????2.00 | ?????- | ????2.00 |
Borneolum Syntheticum | ????1.65 | ????1.50 | ????2.50 | ????1.50 | ????1.60 | ????1.80 | ????1.60 | ????2.00 |
????EDTA-Na2 | ????1.00 | ????1.00 | ????1.00 | ?????- | ????1.00 | ?????- | ?????- | ????1.20 |
Sorbic acid | ????0.56 | ????0.56 | ????0.56 | ?????- | ????0.56 | ????0.56 | ?????- | ????0.56 |
????SOD | ????0.10 | ????0.10 | ?????- | ????0.10 | ?????- | ????0.25 | ????0.25 | ?????- |
????C 4-C 16Perfluor alkane | ????1.80 | ????2.65 | ?????- | ????0.52 | ????1.80 | ?????- | ????1.85 | ?????- |
2. production technology and manufacture process:
(1) dissolving, mixing
Each component (in weight in grams) in the embodiment 1-8 prescription is dissolved in 1000 ml waters, and dissolving is improved after-filtration and is removed behind the insoluble matter stand-byly, changes filtrate over to the oxygen supplement still.
(2) logical oxygen: by at the bottom of the oxygen supplement still in solution slowly bubbling to feed purity be 99.99% oxygen 60 minutes, the control flow is at 1.5 liters/minute, total feeding amount of oxygen is reached more than the 25mg/l, treat that (at this moment still was pressed and reached 1.5kg/cm after theoretical feeding amount surpassed index 10%
2), leaving standstill 30 minutes, sample analysis solution oxygen concentration index enters down the road packaging process after qualified.
Quality standard:
(1) outward appearance: blue, transparent, liquid juice.
(2) pH value: 7.2-7.8
(3) osmotic pressure: 290-310 MOSM/HG
(4) viscosity: be equivalent to the 1%PVA aqueous solution.
(5) Bacteria Detection: qualified (aseptic).
(6) oxygen content: " 25mg/l
(7) eye dripping effect: comfortable, refrigerant, the sensation that makes eye bright is arranged.
The foregoing description only for illustrative purposes, protection scope of the present invention will embody in claims.
Claims (5)
1. the oxygen enrichment eye liquid that relaxes is characterized in that every milliliter of oxygen content is the component that contains following milligram weight in the aqueous solution of 25-30mg/l:
Sodium chloride 5.0-7.0
Boric acid 0-2.5
Borax 0-1.0
Sodium dihydrogen phosphate 0-1.8
Sodium hydrogen phosphate 0-1.5
POLOXAMER407???????3.0-7.0
TW-80??????????????0-4.5
PVP????????????????0-9.5
Hydroxymethyl-propyl cellulose 0-9.0
Hydroxyethyl-cellulose 0-3.5
Taurine 0-3.0
Borneolum Syntheticum 1.5-2.0
EDTA-Na2???????????0-1.2
Sorbic acid 0-0.6
SOD 0-2.5 and
C
4-C
16Perfluor alkane 0-2.8.
2. the oxygen enrichment as claimed in claim 1 eye liquid that relaxes is characterized in that containing in per 1 ml water solution the component of following milligram weight:
Sodium chloride 5.60-7.10
Boric acid 1.60-1.80
Borax 0.6-0.70
*POLOXAMER407??????3.50-5.20
TW-80???????????????1.20-2.60
Hydroxymethyl-propyl cellulose 5.20-7.50
Taurine 2.00
Borneolum Syntheticum 1.50-1.65
EDTA-Na2????????????1.00
Sorbic acid 0.56
SOD?????????????????0.10
C
4-C
16Perfluor alkane 1.8-2.65.
3. the oxygen enrichment as claimed in claim 1 eye liquid that relaxes is characterized in that containing in every ml water solution the component of following milligram weight:
Sodium chloride 5.00-6.50
Boric acid 1.30-2.20
Borax 0.5-0.90
POLOXAMER407????????6.00-6.50
PVP?????????????????6.00-8.20
Hydroxymethyl-propyl cellulose 0-2.20
Taurine 0-2.50
Borneolum Syntheticum 1.50
EDTA-Na2????????????0-1.00
Sorbic acid 0-0.56
SOD 0-0.10 and
C
4-C
16Perfluor alkane 0-0.52.
4. the oxygen enrichment as claimed in claim 1 eye liquid that relaxes is characterized in that containing in every ml water solution the component of following milligram weight:
Sodium chloride 5.00-7.50
Sodium dihydrogen phosphate 1.30-1.70
Sodium hydrogen phosphate 1.20-1.40
POLOXAMER407???????3.00-6.50
TW-80??????????????0-4.30
PVP????????????????0-9.40
Hydroxymethyl-propyl cellulose 0-8.64
Hydroxyethyl-cellulose 0-3.50
Taurine 0-2.65
Borneolum Syntheticum 1.6-2.00
EDTA-Na2???????????0-1.20
Sorbic acid 0.56
SOD????????????????0-0.25
C
4-C
16Perfluor alkane 0-1.85.
5. the oxygen enrichment production technology of eye liquid of relaxing is characterized in that and will be selected from least a (in the weight in grams) of following prescription:
Sodium chloride 5.0-7.0
Boric acid 0-2.5
Borax 0-1.0
Sodium dihydrogen phosphate 0-1.8
Sodium hydrogen phosphate 0-1.5
POLOXAMER407???????3.0-7.0
TW-80??????????????0-4.5
PVP????????????????0-9.5
Hydroxymethyl-propyl cellulose 0-9.0
Hydroxyethyl-cellulose 0-3.5
Taurine 0-3.0
Borneolum Syntheticum 1.5-2.0
EDTA-Na2???????????0-1.2
Sorbic acid 0-0.6
SOD 0-2.5 and
C
4-C
16Perfluor alkane 0-2.8 adds that 1000 ml waters dissolve, leave standstill, to feed oxygen purity be 99.99% oxygen for filtration, filtrate, and the control oxygen flow is at 1.5 liters/minute, be 〉=25mg/l to bottle then until the oxygen content of aqueous solution.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN96116645A CN1185953A (en) | 1996-12-27 | 1996-12-27 | Eye drop containing rich oxygen and preparation thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN96116645A CN1185953A (en) | 1996-12-27 | 1996-12-27 | Eye drop containing rich oxygen and preparation thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CN1185953A true CN1185953A (en) | 1998-07-01 |
Family
ID=5123734
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN96116645A Pending CN1185953A (en) | 1996-12-27 | 1996-12-27 | Eye drop containing rich oxygen and preparation thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1185953A (en) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1312380A4 (en) * | 2000-06-19 | 2003-08-06 | Santen Pharmaceutical Co Ltd | Aseptics |
EP1586307A2 (en) * | 2004-03-23 | 2005-10-19 | Beiersdorf AG | Cosmetic or pharmaceutical compositions containing preserved taurine |
AU2003297511B2 (en) * | 2002-12-20 | 2010-01-21 | Chakshu Research, Inc. | Ophthalmic formulation for the prevention and treatment of ocular conditions |
CN103372230A (en) * | 2012-04-12 | 2013-10-30 | 启东钛力眼镜制品有限公司 | Contact lens care solution |
CN103394077A (en) * | 2010-06-25 | 2013-11-20 | 杨红宇 | Eye drop |
CN103732202A (en) * | 2011-07-26 | 2014-04-16 | 阿勒根公司 | Two part formulation system for ophthalmic delivery |
CN106176593A (en) * | 2016-08-29 | 2016-12-07 | 安徽艾珂尔制药有限公司 | A kind of eye drip Rimactane and preparation method thereof |
CN110200015A (en) * | 2019-05-21 | 2019-09-06 | 何凡 | Antiviral biological peptide conditioning liquid of one kind and its preparation method and application |
-
1996
- 1996-12-27 CN CN96116645A patent/CN1185953A/en active Pending
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1312380A4 (en) * | 2000-06-19 | 2003-08-06 | Santen Pharmaceutical Co Ltd | Aseptics |
AU2003297511B2 (en) * | 2002-12-20 | 2010-01-21 | Chakshu Research, Inc. | Ophthalmic formulation for the prevention and treatment of ocular conditions |
EP1586307A2 (en) * | 2004-03-23 | 2005-10-19 | Beiersdorf AG | Cosmetic or pharmaceutical compositions containing preserved taurine |
CN103394077A (en) * | 2010-06-25 | 2013-11-20 | 杨红宇 | Eye drop |
CN103732202A (en) * | 2011-07-26 | 2014-04-16 | 阿勒根公司 | Two part formulation system for ophthalmic delivery |
US9616017B2 (en) | 2011-07-26 | 2017-04-11 | Allergan, Inc. | Two part formulation system for ophthalmic delivery |
US10314887B2 (en) | 2011-07-26 | 2019-06-11 | Allergan, Inc. | Two part formulation system for ophthalmic delivery |
CN103372230A (en) * | 2012-04-12 | 2013-10-30 | 启东钛力眼镜制品有限公司 | Contact lens care solution |
CN106176593A (en) * | 2016-08-29 | 2016-12-07 | 安徽艾珂尔制药有限公司 | A kind of eye drip Rimactane and preparation method thereof |
CN110200015A (en) * | 2019-05-21 | 2019-09-06 | 何凡 | Antiviral biological peptide conditioning liquid of one kind and its preparation method and application |
CN110200015B (en) * | 2019-05-21 | 2020-10-30 | 乐清市泰博恒电子科技有限公司 | Antiviral biological peptide care solution and preparation method and application thereof |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0799615B1 (en) | Liposome eye drops | |
CN111991415B (en) | Eye care composition and preparation method and application thereof | |
CN1185953A (en) | Eye drop containing rich oxygen and preparation thereof | |
CN108853016A (en) | A kind of ophthalmic solution sodium eye drops and preparation method thereof | |
KR20010020438A (en) | Pourable alginate compositions | |
CN106512062A (en) | Multifunctional contact lenses care solution and preparation method thereof | |
CN110496215A (en) | A kind of aqueous ophthalmic solution and preparation method thereof for treating presbyopia | |
CN101278908B (en) | Eye drop capable of significantly increasing medicament effect | |
CN1943650A (en) | Rose liquid and its eye drops | |
RU2295331C2 (en) | Ocular drops with reparative and anti-glaucoma action | |
CN1237978C (en) | Composite eye-moistening liquid and its application | |
CN115068595A (en) | Anti-radiation composition for eyes and preparation method and application thereof | |
CN1424043A (en) | Kakonein eye drops | |
WO1991017469A1 (en) | Kit for contact lenses | |
CN1215588A (en) | Multifunctional health eye moistening atriphos liquid and preparing method thereof | |
CN103394077A (en) | Eye drop | |
CN1879651A (en) | Eye drop containing micro-elements and preparation method thereof | |
CN1351867A (en) | Levo-potasisum magnesium asparate infusion injection and preparing method | |
US20080152669A1 (en) | Method of Stimulating the Production of Mucin in the Eye of a Patient | |
CN1132574C (en) | Eye medicine prepn. for computer eyesight syndrome and xerophthalmia | |
CN1247264C (en) | Nursing liquor for contact lenses and its production process | |
JP5477798B2 (en) | Eye drops for contact lenses containing a cooling agent | |
CN100522181C (en) | Anoxia and fatigue-resisting health-care oxygen, its preparation and use as health-care product | |
CN1395959A (en) | Eyedrops 'Yanbijing' | |
CN111588693A (en) | Cromolyn sodium eye drops and preparation method thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C01 | Deemed withdrawal of patent application (patent law 1993) | ||
WD01 | Invention patent application deemed withdrawn after publication |